2025
Association Between Relapse and Long-term Kidney Outcomes in IgA Nephropathy
Shen X, Chen P, Hui M, Li J, Hou W, Yang H, Li Y, Liu L, Shi S, Zhou X, Lv J, Zhang H. Association Between Relapse and Long-term Kidney Outcomes in IgA Nephropathy. Kidney Medicine 2025, 101104. DOI: 10.1016/j.xkme.2025.101104.Peer-Reviewed Original ResearchRelapse-free ratePredictors of relapseEndpoint eventsClinicopathological predictorsIgA nephropathyLong-term kidney outcomesAssociated with adverse outcomesNon-relapsing patientsNon-relapse groupCox regression analysisEnd-stage kidney diseaseCorticosteroid-induced remissionLikelihood of relapseLASSO Cox regressionIgAN relapseRelapse incidenceRelapsed patientsRelapse groupEGFR declineRelapse rateKidney outcomesProspective cohortRemissionRelapseClinicopathological indicatorsEfficacy and safety of telitacicept in IgA nephropathy and IgA vasculitis nephropathy in adolescents: a case series
Wu J, Chen P, Liu L, Shi S, Wang F, Zhong X, Lv J, Zhang H. Efficacy and safety of telitacicept in IgA nephropathy and IgA vasculitis nephropathy in adolescents: a case series. Pediatric Nephrology 2025, 1-11. PMID: 40711544, DOI: 10.1007/s00467-025-06905-z.Peer-Reviewed Original ResearchAdolescent patientsGraphical abstractA higher resolution versionMethodsThis retrospective observational studyResultsThe median ageRetrospective observational studyIgA vasculitis nephritisBaseline to follow-upAssociated with substantial reductionsMedian proteinuriaMedian eGFRTreatment discontinuationProteinuria reductionMedian ageEfficacy outcomesMonth 3TelitaciceptCase seriesAdult patientsBaseline characteristicsVasculitis nephritisAdverse eventsTreatment optionsFollow-upSubgroup analysisIgA nephropathyPredictive value of Gd-IgA1, poly-IgA in the treatment of IgA nephropathy with targeted-release formulation budesonide
Chen Q, Chen P, He R, Zan J, Shen X, Lv J, Zhang H. Predictive value of Gd-IgA1, poly-IgA in the treatment of IgA nephropathy with targeted-release formulation budesonide. Clinical Kidney Journal 2025, 18: sfaf203. PMID: 40678796, PMCID: PMC12268327, DOI: 10.1093/ckj/sfaf203.Peer-Reviewed Original ResearchLevels of Gd-IgA1Gd-IgA1Proteinuria reductionPlasma levelsIgA nephropathyGalactose-deficient immunoglobulin A1Estimated glomerular filtration ratePredictive valueTreatment of IgA nephropathyGlomerular filtration rateIgA immune complex formationImmune complex formationProteinuria decreaseProteinuria levelsBiomarker reductionFiltration rateFollow-upTotal IgAProteinuriaRoutine visitsBaseline levelsIgANPlasma samplesMonthsRelease formulationEffects of Podocyte Foot Process Effacement on Kidney Prognosis and Response to Immunosuppressive Therapy in IgA Nephropathy
Guo Y, Ren Y, Shi S, Wang S, Zhou X, Liu L, Lv J, Zhu L, Zhang H. Effects of Podocyte Foot Process Effacement on Kidney Prognosis and Response to Immunosuppressive Therapy in IgA Nephropathy. Kidney Medicine 2025, 7: 101049. PMID: 40740727, PMCID: PMC12309955, DOI: 10.1016/j.xkme.2025.101049.Peer-Reviewed Original ResearchResponse to immunosuppressive therapyFoot process effacementImmunosuppressive therapyKidney prognosisSevere foot process effacementKidney outcomesRisk factorsIgA nephropathyEstimated glomerular filtration rateMonths of follow-upPodocyte injuryPeking University First HospitalComposite kidney outcomeIndependent risk factorGlomerular filtration rateImmunoglobulin A nephropathyEnd-stage kidney diseasePodocyte lesionsContinuous net reclassification improvementPodocyte foot process effacementIntegrated discrimination improvementNet reclassification improvementOverall cohortAbstractText Label="ExposureAbstractText Label="RESULTS"The Proportion of New-Onset Microangiopathic Lesions in IgA Nephropathy is Increased After COVID-19 Pandemic in China
Wu J, Shi S, Zhou X, Liu L, Lv J, Zhu L, Wang S, Zhang H. The Proportion of New-Onset Microangiopathic Lesions in IgA Nephropathy is Increased After COVID-19 Pandemic in China. Kidney Medicine 2025, 7: 101043. PMID: 40746936, PMCID: PMC12311513, DOI: 10.1016/j.xkme.2025.101043.Peer-Reviewed Original ResearchMA lesionsCOVID-19 infectionMultivariate logistic regressionTotal biopsyRisk factorsThrombotic microangiopathyIgA nephropathyLogistic regressionStage 3Cochran-Armitage trend testDevelopment of IgANMicroangiopathic lesionsStage 2AbstractText Label="ExposureAbstractText Label="RESULTS"Stage 3aStage 3bStage 1AAbstractText Label="ConclusionsC3 depositionIgANMedical recordsAbstractText Label="LimitationsBiopsyLesionsExpanding the spectrum of genetic causes of DNA-specific exonuclease TREX1 variants in thrombotic microangiopathy
Song Z, Liu Z, Li M, Li Y, Li J, Lv J, Zhang H, Zhou X. Expanding the spectrum of genetic causes of DNA-specific exonuclease TREX1 variants in thrombotic microangiopathy. Kidney International 2025, 108: 317-320. PMID: 40383229, DOI: 10.1016/j.kint.2025.04.014.Peer-Reviewed Original ResearchANCA-associated vasculitisThrombotic microangiopathyIgA nephropathyTREX1 variantsMicroangiopathic lesionsSpectrum of genetic causesAnti-complement therapyRegulate immune responsesPlasma exchangeMicrovascular thrombiGenome integrityC3 glomerulopathyTailored therapyEndothelial damagePathogenic variantsMicrovascular diseaseImmune regulationImmune responseGenetic causeMicroangiopathyCoagulation pathwayTherapeutic avenuesNephropathyCytosolic DNAPatientsNew thoughts on the intestinal microbiome-B cell-IgA axis and therapies in IgA nephropathy
Dang S, Zhang X, Zhang Y, Zhang H. New thoughts on the intestinal microbiome-B cell-IgA axis and therapies in IgA nephropathy. Autoimmunity Reviews 2025, 24: 103835. PMID: 40360014, DOI: 10.1016/j.autrev.2025.103835.Peer-Reviewed Original ResearchEnd-stage renal diseaseIgA nephropathyLack of effective early diagnosisPrognosis of patientsPathogenesis of IgANPathogenic IgAIntestinal flora dysbiosisImmune milieuMucosal infectionsEffective early diagnosisRetrospective reviewChronic glomerulonephritisRenal diseaseIgA depositionChronic progressionEarly diagnosisPathological featuresTherapeutic approachesPathogenic mechanismsIgANTherapeutic initiativesIgAIgA productionMesangial regionNephropathyLoss of GalNAc-T14 links O-glycosylation defects to alterations in B cell homing in IgA nephropathy
Prakash S, Steers N, Li Y, Sanchez-Rodriguez E, Verbitsky M, Robbins I, Simpson J, Pathak S, Raska M, Reily C, Ng A, Liang J, DeMaria N, Katiraei A, O'Stevens K, Fischman C, Shapiro S, Kodali S, McCutchan J, Park H, Eliby D, Delsante M, Allegri L, Fiaccadori E, Bodria M, Marasa M, Raveche E, Julian B, Uhlemann A, Kiryluk K, Zhang H, D'Agati V, Sanna-Cherchi S, Novak J, Gharavi A. Loss of GalNAc-T14 links O-glycosylation defects to alterations in B cell homing in IgA nephropathy. Journal Of Clinical Investigation 2025, 135: e181164. PMID: 40153534, PMCID: PMC12077892, DOI: 10.1172/jci181164.Peer-Reviewed Original ResearchConceptsO-glycosylationAberrant O-glycosylationIgA nephropathyMucosal immunityN-acetylgalactosaminyltransferaseElevated serum IgA levelsAdoptive-transfer experimentsB-cell homingSerum IgA levelsProtein O-glycosylationIgA-producing cellsGlomerular IgA depositionImmune-complex formationPathogenesis of IgANIgA1 hinge regionIgA1-producing cellsPeripheral bloodImpaired homingKidney injuryB cellsB lymphocytesIgA levelsLoF variantsIgA depositionGalNAc-T14Red blood cell casts on kidney biopsy and progression of IgA nephropathy
Yao Y, Tang C, Shi S, Chen P, Zhou X, Lv J, Liu L, Zhang H. Red blood cell casts on kidney biopsy and progression of IgA nephropathy. Nephrology Dialysis Transplantation 2025, 40: 1570-1579. PMID: 39909472, DOI: 10.1093/ndt/gfaf023.Peer-Reviewed Original ResearchComposite kidney endpointRed blood cell castsMedian Follow-UpImmunosuppressive therapyKidney endpointsCell castsFollow-upIgA nephropathyKidney diseaseProgression of IgA nephropathyDisease progression of patientsCox regression analysisEnd stage kidney diseaseKidney disease progressionAcute active lesionsStage kidney diseaseProgression of patientsRenal prognosisCrescentic lesionsDeath due to kidney diseaseKidney biopsyKidney outcomesUnivariate analysisActive lesionsMultivariate analysisThe evolving understanding of systemic mechanisms in organ-specific IgA nephropathy: a focus on gut-kidney crosstalk
Wang X, Zhou X, Qiao X, Falchi M, Liu J, Zhang H. The evolving understanding of systemic mechanisms in organ-specific IgA nephropathy: a focus on gut-kidney crosstalk. Theranostics 2025, 15: 656-681. PMID: 39744688, PMCID: PMC11671385, DOI: 10.7150/thno.104631.Peer-Reviewed Original ResearchConceptsGut-kidney crosstalkExploration of gut microbiotaGut microbiotaKidney diseaseMechanism of IgANIntestinal microbiomeSignaling pathwayIgA nephropathyInter-organ crosstalkEfficient therapeutic strategiesPrognosis of patientsProgression of IgANElaborate mechanismsTherapeutic strategiesIgAN pathogenesisIgANCrosstalkMicrobiomeMicrobiotaMultiple organsKidneyProbioticsNephropathyDiseaseMechanism
2024
Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy
Perkovic V, Barratt J, Rovin B, Kashihara N, Maes B, Zhang H, Trimarchi H, Kollins D, Papachristofi O, Jacinto-Sanders S, Merkel T, Guerard N, Renfurm R, Hach T, Rizk D. Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy. New England Journal Of Medicine 2024, 392: 531-543. PMID: 39453772, DOI: 10.1056/nejmoa2410316.Peer-Reviewed Original ResearchProtein-to-creatinine ratioUrinary protein-to-creatinine ratioIgA nephropathyMonth 9Biopsy-confirmed IgA nephropathySupportive therapyTreatment periodDouble-blind treatment periodSecondary end point analysisTrial populationIncidence of adverse eventsIncreased risk of infectionPlacebo-controlled trialSecondary end pointsComplement pathway inhibitionProportion of patientsPathogenesis of IgA nephropathyKidney replacement therapyClinically meaningful reductionsInterim efficacy analysisRisk of infectionDouble-blindPlacebo groupSafety findingsEfficacy analysisAtrasentan in Patients with IgA Nephropathy
Heerspink H, Jardine M, Kohan D, Lafayette R, Levin A, Liew A, Zhang H, Lodha A, Gray T, Wang Y, Renfurm R, Barratt J. Atrasentan in Patients with IgA Nephropathy. New England Journal Of Medicine 2024, 392: 544-554. PMID: 39460694, DOI: 10.1056/nejmoa2409415.Peer-Reviewed Original ResearchIgA nephropathyAdverse eventsInterim analysisBiopsy-proven IgA nephropathyInterim analysis of dataBaseline to weekBody-surface areaPercentage of patientsProtein-to-creatinine ratioUrinary protein-to-creatinine ratioMean percentage changeCases of cardiac failureRisk of kidney failureClinically meaningful reductionsTrial regimenPlacebo groupAntagonist atrasentanDouble-blindBetween-group differencesCardiac failureReduce proteinuriaFluid retentionSevere proteinuriaAtrasentan groupAtrasentanStudy Design and Baseline Characteristics of ALIGN, a Randomized Controlled Study of Atrasentan in Patients With IgA Nephropathy
Heerspink H, Jardine M, Kohan D, Lafayette R, Levin A, Liew A, Zhang H, Noronha I, Trimarchi H, Hou F, Renfurm R, Gray T, Camargo M, Barratt J. Study Design and Baseline Characteristics of ALIGN, a Randomized Controlled Study of Atrasentan in Patients With IgA Nephropathy. Kidney International Reports 2024, 10: 217-226. PMID: 39810771, PMCID: PMC11725817, DOI: 10.1016/j.ekir.2024.10.004.Peer-Reviewed Original ResearchRenin-angiotensin system inhibitorsEndothelin-AStable doseIgA nephropathyEndothelin-A receptor antagonistSodium-glucose cotransporter-2 inhibitorsPlacebo-controlled clinical trialRenin-angiotensin system inhibitor therapyBiopsy-proven IgANBaseline to weekCotransporter-2 inhibitorsMethods Eligibility criteriaKidney function lossRandomized Controlled StudyDouble-blindReceptor antagonistReduce proteinuriaEGFR changeBaseline characteristicsSystem inhibitorsIgAN populationAtrasentanKidney functionKidney inflammationClinical trialsTargeting APRIL in the treatment of glomerular diseases
Cheung C, Barratt J, Lafayette R, Liew A, Suzuki Y, Tesař V, Trimarchi H, Wong M, Zhang H, Rizk D. Targeting APRIL in the treatment of glomerular diseases. Kidney International 2024, 106: 806-818. PMID: 39182759, DOI: 10.1016/j.kint.2024.08.012.Peer-Reviewed Original ResearchGlomerular diseaseB cell depletion strategiesCytokine B cell-activating factorDeleterious host immune responsesFunctionality of humoral immunityMemory B-cell functionB-cell activating factorProliferation inducing ligandTreatment of glomerular diseasesB cell functionB cell developmentB cell survivalImmunoglobulin class switchingResponse to vaccinationClinical trial dataHost immune responseTumour necrosis factor (TNF)-superfamilyImmunomodulatory approachesAutoimmune diseasesClinical developmentInducing ligandIgA nephropathyHumoral immunityTherapeutic inhibitionClass switchingThe pathogenesis of IgA nephropathy and implications for treatment
Cheung C, Alexander S, Reich H, Selvaskandan H, Zhang H, Barratt J. The pathogenesis of IgA nephropathy and implications for treatment. Nature Reviews Nephrology 2024, 21: 9-23. PMID: 39232245, PMCID: PMC7616674, DOI: 10.1038/s41581-024-00885-3.Peer-Reviewed Original ResearchIgA nephropathyComplement activationDisease pathogenesisB cell primingMucosal immune systemPathogenesis of IgA nephropathyChronic kidney diseaseTargeting different pathwaysPlasma cellsPrimary glomerulonephritisTreatment optionsIgA antibodiesKidney diseaseImmune complexesTriggering inflammationKidney damageGut mucosaObservational studyKidney failureImmune systemLong-term outlookPathway activationPathogenesisIgANNephropathyLactobacillus casei Cell Wall Extract and Production of Galactose-Deficient IgA1 in a Humanized IGHA1 Mouse Model
Li R, Wang M, Li J, Zhu L, Xie X, Wang H, Zhang X, Tian W, Zhang Y, Dong Y, Zan J, Li H, Zhang Y, Zhou X, Shi S, Shu C, Liu L, Jin J, Lv J, Zhang H. Lactobacillus casei Cell Wall Extract and Production of Galactose-Deficient IgA1 in a Humanized IGHA1 Mouse Model. Journal Of The American Society Of Nephrology 2024, 36: 60-72. PMID: 39172518, PMCID: PMC11706567, DOI: 10.1681/asn.0000000000000465.Peer-Reviewed Original ResearchLactobacillus casei cell wall extractAssociated with hematuriaGalactose-deficient IgA1Mouse modelIgA nephropathyWild-type C57BL/6J miceFactor H mutationCell wall extractsCFA-treated miceGd-IgA1 levelsElevated levelsGalactose-deficient IgA1 levelsIgA1-immune complexesModel of IgA nephropathyMouse chromosomal lociGlomerular mesangial areasMonths of ageTransgenic mouse modelHuman IgA1Hinge regionHuman IgA1 heavy chainMucosal sitesGd-IgA1Immune reactivityGlomerular alterationsCorrelation of Urinary Soluble CD163 Levels With Disease Activity and Treatment Response in IgA Nephropathy
Li J, Lv J, Wong M, Shi S, Zan J, Monaghan H, Perkovic V, Zhang H, Group T, Zhang H, Perkovic V, Agarwal R, Barbour S, Cattran D, Cass A, Chan T, Feehally J, Glassock R, Hladunewich M, Hooi L, Jardine M, Jha V, Johnson D, Levin A, Liu Z, Lv J, Monaghan H, Reich H, Remuzzi G, Wheeler D, Wong M, Woodward M, Wu Y, Zhao M. Correlation of Urinary Soluble CD163 Levels With Disease Activity and Treatment Response in IgA Nephropathy. Kidney International Reports 2024, 9: 3016-3026. PMID: 39430181, PMCID: PMC11489515, DOI: 10.1016/j.ekir.2024.07.031.Peer-Reviewed Original ResearchCorticosteroid therapyMacrophage infiltrationIgA nephropathyResponse to immunosuppressive therapyRisk of serious adverse eventsKidney macrophage infiltrationSoluble CD163 levelsUrinary soluble CD163Glomerular macrophage infiltrationSerious adverse eventsDosage of corticosteroidsRisk of kidney failureResponse of steroid therapyCorrelation of baselineReduced riskAssociated with greater benefitCD163 levelsProteinuria remissionImmunosuppressive therapySteroid therapyClinical remissionGlucocorticoid therapySoluble CD163IgAN cohortPlacebo groupClinical Implications of C2 Lesion in IgA Nephropathy: A Cohort Study
Wang Z, Zhou X, Shi S, Liu L, Lv J, Zhang H. Clinical Implications of C2 Lesion in IgA Nephropathy: A Cohort Study. American Journal Of Nephrology 2024, 55: 529-538. PMID: 39074466, DOI: 10.1159/000540268.Peer-Reviewed Original ResearchConceptsEnd-stage kidney diseaseC2 lesionsCohort studyCox regressionMonths prior to biopsyPeking University First HospitalProportion of crescentsMultivariate Cox regressionProspective cohort studyEffective treatment strategiesKidney prognosisImmunosuppressive treatmentRenal prognosisT2 lesionsMean proteinuriaCombined steroidCrescentic lesionsOxford classificationGlomerular crescentsClinical prognosisUnivariate analysisPathological findingsClinical significanceIgA nephropathyKidney functionUromodulin and progression of IgA nephropathy
Chen Z, Xu L, Du W, Ouyang Y, Gu X, Fang Z, Yu X, Li J, Xie L, Jin Y, Ma J, Wang Z, Pan X, Zhang W, Ren H, Wang W, Chen X, Zhou X, Zhang H, Chen N, Xie J. Uromodulin and progression of IgA nephropathy. Clinical Kidney Journal 2024, 17: sfae209. PMID: 39145144, PMCID: PMC11322676, DOI: 10.1093/ckj/sfae209.Peer-Reviewed Original ResearchEnd-stage renal diseaseSingle-nucleotide polymorphismsIgAN patientsAllele-specific enhancer activityKidney functionAssociated with renal function deteriorationGenome-wide association studiesFunction of genetic variationBiopsy-proven IgAN patientsProgression of IgA nephropathyRenal pathological dataEnd-stage renal disease patientsRenal function deteriorationTubular epithelial cellsEnhanced activityRenal tubular epitheliumIgAN progressionUromodulin expressionNo significant differenceGenetic variationRuijin HospitalUromodulin levelsPathological dataIgA nephropathyRenal diseaseExploring Novel Adverse Events of Nefecon
Wang J, Zhang Z, Liu X, Shi S, Lv J, Zhang Y, Zhang H. Exploring Novel Adverse Events of Nefecon. Kidney International Reports 2024, 9: 2705-2717. PMID: 39291217, PMCID: PMC11403076, DOI: 10.1016/j.ekir.2024.07.006.Peer-Reviewed Original ResearchAdverse eventsFood and Drug AdministrationFDA Adverse Event Reporting SystemSystem organ classNovel adverse eventsSubgroup analysisDisproportionate analysisFailure type profileUS Food and Drug AdministrationUS FDA Adverse Event Reporting SystemAdverse Event Reporting SystemMedical Dictionary of Regulatory ActivitiesEuropean Medicines AgencyClinical vigilanceEvent Reporting SystemSafety profileCumulative incidencePostmarketing dataIgA nephropathyClinical eventsPositive PTDrug AdministrationRelative riskMedicines AgencyClinical priority
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply